Cysview

PATIENT INFORMATION

Ask patients if they have:

  • a diagnosis or a family history of porphyria
  • allergy to aminolevulinic acid or prior exposure to Cysview (hexaminolevulinate hydrochloride intravesical solution)
  • gross hematuria
  • had BCG immunotherapy or chemotherapy within the bladder.

Inform patients that Cysview (hexaminolevulinate hydrochloride intravesical solution) should be retained in the bladder for 1 hour from instillation of Cysview (hexaminolevulinate hydrochloride intravesical solution) to the start of the cystoscopic procedure. If the patient cannot hold Cysview (hexaminolevulinate hydrochloride intravesical solution) for 1 hour, but needs to void and expel Cysview (hexaminolevulinate hydrochloride intravesical solution) from the bladder, he or she may void and should then inform a health care professional [see DOSAGE AND ADMINISTRATION].

Last reviewed on RxList: 6/29/2010
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.


NIH talks about Ebola on WebMD